Cancer increases VTE risk (Illustration: MostPhotos.com)
In this project, we use data from the Tromsø study, the Trøndelag Health Study (HUNT) and the Scandinavia Thrombosis and Cancer (STAC) cohort, which is a merged cohort of Tromsø, HUNT and the Diet Cancer and Health Study (DCH, Denmark). We investigate the epidemiology and risk factors of occult and over cancer-associated VTE, as well as interactions of cancer and genetic risk factors on VTE risk.
Principal Investigator: John-Bjarne Hansen
External collaborators: Nick van Es (Amsterdam University Medical Center), Søren Risom Kristensen , Inger Lise Gade (Aalborg University, Denmark), Kristian Hveem (HUNT Center for Clinical and Molecular Epidemiology), Frits Rosendaal and Suzanne Cannegieter (Leiden University Medical Center)
Publications:
Crobach et al. Survival after cancer-related venous thrombosis: the Scandinavian Thrombosis and Cancer Study. Blood Adv . 2023; 7 : 4072-9.
Skille et al. Prothrombotic genotypes and risk of venous thromboembolism in occult cancer. Thromb Res . 2021; 205 : 17-23.
Paulsen et al. Association of smoking and cancer with the risk of venous thromboembolism: the Scandinavian Thrombosis and Cancer cohort. Sci Rep . 2021; 11 : 18752.
Skille et al. Genetic variation of platelet glycoprotein VI and the risk of venous thromboembolism. Haematologica . 2020; 105 : e358-e60.
Skille et al. Combined effects of five prothrombotic genotypes and cancer on the risk of a first venous thromboembolic event. J Thromb Haemost . 2020; 18 : 2861-9.
Paulsen et al. Fibrinogen gamma gene rs2066865 and risk of cancer-related venous thromboembolism. Haematologica . 2020; 105 : 1963-8.
Gran et al. Prothrombotic genotypes and risk of venous thromboembolism in cancer. Thromb Res . 2018; 164 Suppl 1 : S12-S8.
Gade et al. Long-Term Incidence of Venous Thromboembolism in Cancer: The Scandinavian Thrombosis and Cancer Cohort. TH Open . 2018; 2 : e131-e8.
Gran et al. Occult cancer-related first venous thromboembolism is associated with an increased risk of recurrent venous thromboembolism. J Thromb Haemost . 2017; 15 : 1361-7.
Gran et al. D-dimer measured at first venous thromboembolism is associated with future risk of cancer. Haematologica . 2016; 101 : e473-e5.
Gade et al. Epidemiology of venous thromboembolism in hematological cancers: The Scandinavian Thrombosis and Cancer (STAC) cohort. Thromb Res . 2017; 158 : 157-60.
Gran et al. Joint effects of cancer and variants in the factor 5 gene on the risk of venous thromboembolism. Haematologica . 2016; 101 : 1046-53.
Blix et al. Impact of time since diagnosis and mortality rate on cancer-associated venous thromboembolism: the Scandinavian Thrombosis and Cancer (STAC) cohort. J Thromb Haemost . 2018; 16 : 1327-35.
Gade et al. The impact of initial cancer stage on the incidence of venous thromboembolism: the Scandinavian Thrombosis and Cancer (STAC) Cohort. J Thromb Haemost . 2017; 15 : 1567-75.
Jensvoll et al. Existing data sources in clinical epidemiology: the Scandinavian Thrombosis and Cancer Cohort. Clin Epidemiol . 2015; 7 : 401-10.
Jensvoll et al. Platelet count measured prior to cancer development is a risk factor for future symptomatic venous thromboembolism: the Tromso Study. PloS one . 2014; 9 : e92011.
Blix et al. The increased risk of venous thromboembolism by advancing age cannot be attributed to the higher incidence of cancer in the elderly: the Tromso study. Eur J Epidemiol . 2014; 29 : 277-84
Blix et al. White blood cell count measured prior to cancer development is associated with future risk of venous thromboembolism--the Tromso study. PloS one . 2013; 8 : e73447.
